Fifth Third Bancorp significantly reduced its stake in Cadence Design Systems (NASDAQ:CDNS) by 64.0% in the third quarter, selling 181,756 shares and holding 102,190 shares valued at $33.74 million. Other institutional investors showed mixed activity, with some increasing and others initiating positions. Analysts have a "Moderate Buy" rating for CDNS with an average target price of $410.05, despite recent insider sales and a slight uptick in the stock's value.

Exide Industries has successfully integrated over 120,000 dealers and 20,000 mechanics onto a unified customer operations platform powered by Salesforce, encompassing sales, service, field operations, and its partner ecosystem across India. This deployment has significantly reduced service response times and improved complaint resolution by over 30 percent. The company now plans to introduce AI agents to further enhance sales, customer support, and various service operations in response to India's evolving mobility landscape.

Summit Insights has downgraded Applied Materials (AMAT) to Hold from Buy, citing limited upside to the company's fiscal 2027 outlook due to cleanroom constraints. The firm believes that much of the anticipated wafer fab equipment (WFE) market growth is already priced into the shares, with capex intensity expected to favor lithography over etch and deposition in 2027.

Credo Technology Group (CRDO) has introduced new Open Compute Project (OCP) approved standards for enhanced telemetry in optical transceivers, a development that aligns with its focus on AI data center connectivity. While these standards are beneficial for Credo's market positioning, the immediate factors influencing its investment case remain its upcoming fiscal Q2 results, expected on December 1, 2026, and its ability to meet revenue and margin guidance amidst AI infrastructure demand. The article suggests that a strong performance in these areas, particularly concerning AI orders and gross margins above 65%, will be crucial in sustaining the current high-risk, execution-heavy investment thesis, which already projects a significant potential upside.

Citizens & Northern Corp initiated a new position in Tesla during Q3, purchasing 3,602 shares valued at approximately $1.28 million. Institutional investors now hold 66.2% of Tesla's stock, and analysts maintain a "Moderate Buy" consensus with an average price target of $414.51. Tesla's recent earnings beat estimates by two cents per share, though revenue was slightly below forecasts.

Eurizon Capital SGR S.p.A. significantly increased its stake in T-Mobile US, Inc. by 22.5% in the third quarter of 2026, acquiring an additional 290,279 shares to hold a total of 1,581,863 shares valued at approximately $258 million. T-Mobile reported strong third-quarter earnings, beating analyst estimates with an EPS of $3.22 and a 7.4% year-over-year revenue increase to $23.58 billion. The company also raised its quarterly dividend to $1.17 per share.

Roth Capital has initiated coverage on Analog Devices (ADI) with a "Buy" rating and set a price target of $505.00. The article details historical stock performance after analyst coverage notes and other headlines, noting a mixed short-term reaction but a median move of 2.2% in either direction following earlier news. It also provides context on what initiation of coverage means and links to further research resources for ADI.

Ritholtz Wealth Management significantly increased its stake in Salesforce Inc. during the third quarter, acquiring an additional 7,808 shares to bring its total holdings to 22,990 shares valued at approximately $5.28 million. Institutional investors now collectively own 80.43% of the company's stock, reflecting strong confidence in the CRM provider. Salesforce has received a consensus "Moderate Buy" rating from analysts with an average price target of $278.98, following a quarter where it reported EPS of $5.90, well above the consensus, and a 10.8% year-over-year revenue increase to $11.35 billion.

Moving iMage Technologies, Inc. (MITQ) will report its Q1 fiscal 2027 results and host an investor conference call on November 13, 2026, at 11:00 am ET. Management will provide prepared remarks followed by a Q&A session. Details for accessing the call, including dial-in numbers and a replay option, are provided.

Wells Fargo has initiated coverage on Korsana Biosciences (NASDAQ:KRSA) with an "overweight" rating and a $44 price target, indicating a potential 41% upside. The biotech firm's lead asset, KRSA-028, is being developed for Alzheimer's Disease and utilizes a transferrin receptor shuttle to improve drug delivery and amyloid beta clearance. Other analysts from UBS, Stifel, TD Cowen, and Wedbush have also issued positive ratings, citing the drug's innovative approach and the high unmet need in Alzheimer's treatment.